Mild CMV reactivation was associated with beneficial effects, while severe cases required treatment, which increased the risk of toxicity and infections.

A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, representing a potential paradigm shift if approved by the FDA, while highlighting ...

Of 34 CMML treatment-naïve participants enrolled and treated with lenzilumab plus azacitidine, 22 have evaluable responses in the first twelve months of follow-up - Building upon previously reported ...

Gaining insights into the complex pathways and key cell populations involved in immune dysregulation can aid the development ...

ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy ...

Studies indicate that children living near oil and gas wells have a significantly higher risk of developing acute lymphocytic leukemia, prompting calls for better regulations and health protections.

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...